diabetestalk.net

Metformin In Japan

Diabetes In Japan

Diabetes In Japan

Diabetes in Japan is a major problem, with the government taking active measures to curb the disease. Many attribute the high consumption of white rice and noodles as one of the culprits. Japan has many healthy options to reduce the risk of diabetes and keep it under control when it does arise. What is diabetes? Diabetes mellitus is characterized as the inability of the body to produce sufficient insulin, or to use it properly. The function of the hormone insulin is to let your cells take up and process glucose, an essential unit of energy. Deprived of glucose, cells start to think that they’re starving, which can lead to a variety of complications. For instance, the body will convert fats and proteins into sugar, producing chemicals known as ketones in the process. Accumulation of ketones causes the blood to become acidic, a condition called ketoacidosis, which in turn can induce a comatose state and later, death. There are two major types of diabetes, Type I and Type II. Type I diabetes is often diagnosed in childhood or early adulthood, and is the result of the body’s immune system accidentally attacking and destroying the insulin-producing beta cells of the pancreas. This condition is less common than Type II diabetes, which usually manifests itself in adulthood and is caused by either the body becoming resistant to insulin or not producing enough of it. The mechanisms behind these processes are not yet fully elucidated, but factors such as genetics, obesity, and sedentary lifestyle are thought to play a role. What role does diabetes in Japan play? In 2015, there were 7.2 million cases of diabetes in Japan. This astonishing number is the reason that Japan has the fifth largest population of diabetic patients worldwide. The increase in prevalence of diabetes can Continue reading >>

Effects Of Dosage And Dosing Frequency On The Efficacy And Safety Of Highdose Metformin In Japanese Patients With Type 2 Diabetes Mellitus

Effects Of Dosage And Dosing Frequency On The Efficacy And Safety Of Highdose Metformin In Japanese Patients With Type 2 Diabetes Mellitus

Effects of dosage and dosing frequency on the efficacy and safety of highdose metformin in Japanese patients with type 2 diabetes mellitus Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka, Japan Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka, Japan Please review our Terms and Conditions of Use and check box below to share full-text version of article. I have read and accept the Wiley Online Library Terms and Conditions of Use. Use the link below to share a full-text version of this article with your friends and colleagues. Learn more. Differences in the efficacy and safety of antidiabetic drugs among different ethnic groups are well documented. Metformin is widely used in the treatment of type 2 diabetes in Western countries, but high doses of metformin have been approved only recently for clinical use in Japan. The aim of the present study was to investigate the effects of dosage and dosing frequency on the efficacy and safety of highdose metformin in Japanese patients. A total of 71 Japanese patients with type 2 diabetes were prospectively studied for the effects of dosage and dosing frequency on the efficacy and safety of metformin during hospitalization. Dose effects were studied in 27 patients treated with 0, 500, 1,000, 1,500 and 2,250 mg/day of metformin. The effect of dosing frequency was compared in 56 patients with 1,500 mg/day of metformin administered either two or three times per day. Significant dosedependent improvement in daily profiles of blood glucose was observed with metformin dosages up to 1,500 mg/day, with a trend towards further improvement observed at 2,250 mg/day. The efficacy of 1,500 mg of metformin was comparable when the drug was administe Continue reading >>

Efficacy And Safety Of Liraglutide Monotherapy Compared With Metformin In Japanese Overweight/obese Patients With Type 2 Diabetes

Efficacy And Safety Of Liraglutide Monotherapy Compared With Metformin In Japanese Overweight/obese Patients With Type 2 Diabetes

Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Department of Internal Medicine, Yokohama Municipal Citizens Hospital, Kanagawa, Japan Department of Internal Medicine, Eiju General Hospital, Tokyo, Japan Department of Internal Medicine, Japan Community Health Care Organization Saitama Medical Center, Saitama, Japan Department of Internal Medicine, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tokyo, Japan Diabetes Center, Eiju General Hospital, Tokyo, Japan Department of Internal Medicine, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan JOURNALS FREE ACCESS Advance online publication released J-STAGE: - [Advance Publication] Released: February 26, 2015 received: November 10, 2014 corrected: - accepted: February 06, 2015 There is little information on direct comparison between metformin and glucagon-like peptide-1 (GLP-1) receptor agonists in the Asian population. This study examined the efficacy and safety of liraglutide monotherapy compared with metformin monotherapy in overweight/obese Japanese patients with type 2 diabetes (T2DM). The study was a 24-week, open-labeled, randomized controlled study. Overweight or obese patients with T2DM aged 20- Continue reading >>

Biobank Japan - Pgrn Hub

Biobank Japan - Pgrn Hub

The Ministry of Education, Culture, Sports, Science and Technology (MEXT) established the BioBank Japan Project in 2003. The BioBank Japan represents a large repository with human biospecimens, such as DNA and serum, and relevant medical record information. The goal of the project is to enable the practical implementation of individually optimized medical treatment (i.e. tailor-made medicine). Many papers have been published as a result of the rich resources available at BioBank Japan, which target 38 diseases from over 200,000 patients. This project was lead by Yusuke Nakamura (2003-2011) and currently by Michiaki Kubo (2011-present). Both leaders have established many PGRN-RIKEN collaborative studies since 2008 and are continuing to do so in various projects . Request to collaborate with the BioBank Japan The BioBank Japan Project has genetic information of genome-wide genotyping data in 200,000 patients and the clinical information about the various diseases that can be found in recent Journal of Epidemiology (see here ). If you have a study that could potentially benefit from this resource, we would appreciate hearing from you. Please send an e-mail to Dr. Sook Wah Yee, [email protected] . In the e-mail, please describe the goals of the project and the information (types of data, number of patients/samples, phenotypes, genotypes) that you need. We will then make an assessment of the kind of information that is needed and whether BioBank Japan has the information and/or associated data. Continue reading >>

Safe Pharmacy To Buy Generics Price Glucophage 850 Mg Online

Safe Pharmacy To Buy Generics Price Glucophage 850 Mg Online

Safe Pharmacy To Buy Generics Price Glucophage 850 mg online Best Pharmacy To Purchase Glucophage Cheap. Glucophage (Metformin) is used to treat a type of diabetes mellitus (sugar diabetes) called type 2 diabetes. With this type of diabetes, insulin produced by the pancreas is not able to get sugar into the cells of the body where it can work properly. Generic Glucophage is the first-line drug of choice for type 2 diabetes. Glucophage may also be marketed as: Diabex, Diaformin, Fortamet, Metformin, Riomet. *Glucophage is manufactured by Bristol-Myers Squibb. Follow this link to Order Generic Glucophage (Metformin) NOW! Metformin Much Prescription Cost, Order Online Glucophage Austria, Generic Glucophage Kopen, Kp Generic Glucophage Houston, Order Cheap Glucophage Danmark, Cheap Glucophage Safe, Buy Metformin Online Reviews, Do You Need A Prescription To Buy Metformin, Achat Metformin Pharmacie Francaise, Buy Online Glucophage Houston, Buy The Cheapest Metformin, Where To Buy Cheap Glucophage Suisse, Generic Metformin Online Cheap, Where To Get Online Glucophage Angleterre, Where To Purchase Online Glucophage Gb, Buy Glucophage Over Internet, Where To Purchase Cheap Glucophage San Diego, Brand Metformin Wholesale Price, France Glucophage Where To Order, Metformin Kopen, Cheap Metformin Paypal, Billig Cheap Glucophage Belgium, Achat De Metformin, Best Website Buy Glucophage, Buy Cheap Brand Metformin, How Much Does Glucophage Cost Online, Order Glucophage Generic Online, Generic Metformin Order, Glucophage Low Cost Generic, Glucophage Metformin Cheap, Generic Glucophage Cheap Prices, Real Glucophage For Sale, Acheter Metformin Toute Confiance, Metformin Daily Cost, Buying Real Glucophage Online, Buy Glucophage Online Pharmacy, Glucophage Medication Cost, Branded Metformi Continue reading >>

Jentadueto (linagliptin/metformin Hydrochloride) Tablets Receive Approval For The Treatment Of Adults With Type 2 Diabetes In Europe

Jentadueto (linagliptin/metformin Hydrochloride) Tablets Receive Approval For The Treatment Of Adults With Type 2 Diabetes In Europe

Jentadueto (linagliptin/metformin hydrochloride) tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe New treatment will provide a single tablet option for adults who need to reduce their blood sugar Ingelheim, Germany, 25 July, 2012 Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet.1Linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes.1 "We're delighted that linagliptin/metformin hydrochloride (HCl) will soon be available across Europe to help people with Type 2 Diabetes," said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. "Many patients need more than one treatment to adequately manage their diabetes. Linagliptin/metformin hydrochloride (HCl) offers a simplified, single tablet dosing option, to improve glycaemic control and with a favourable side effect profile." The European Commission has approved linagliptin/metformin hydrochloride (HCl) for use alongside diet and exercise to improve glycaemic control in adults with Type 2 Diabetes who are inadequately controlled on their maximal tolerated dose of metformin alone, metformin and a sulphonylurea, or those already being treated with the combination of linagliptin and metformin.1It may also be used with a sulphonylurea. In clinical trials, statistically significant, placebo-corrected mean reductions in haemoglobin A1c (HbA1c or A1C) levels of -1.7 percent were observed in patients with inadequate glycaemic control when the maximum dose of 2.5 mg linagliptin/1,000 mg metformin HCI was administered t Continue reading >>

10 Things To Know About Medication In Japan

10 Things To Know About Medication In Japan

A headache or a cold can spoil your day! Whether you are traveling in Japan or whether you live there, it is useful to know how and where to get medicines. With Expatilt, prepare your trip and stay in shape to make the most of your visit in Japan. Here are 10 tips to understand the use of drugs and pharmacies in the land of the rising sun! 1. Where I can buy medicines in Japan? In Japan, drugs can be purchased in several types of stores: - Big pharmacy chains: Matsumoto Kiyoshi (マツモトキヨシ) is the most popular one in Japan for example. Their shops are present on the whole island and provide not only the original brands of drugs and medicines but also many Japanese and international cosmetics and beauty products. Others chains in Japan are: SunDrug, Sugi Drug Group and Tsuruha Drug. - Hospitals’ pharmacies: most of hospitals have an in-house pharmacy so that you can collect the drugs, and pay for it with the consultation at the same time. - Others pharmacies: unlike in Europe or in the United States of America, there are no specific signs or symbol to distinguish pharmacies in Japan. Each pharmacy is identified by a different symbol and logo depending on the pharmaceutical laboratory they are associated to. Thus, some have a rabbit (symbol of the pharmaceutical company SS Seyaku) and others a frog, an elephant or a hippopotamus. You can also find some pharmaceutical products in supermarkets and konbinis, but this does not concern products against fever. In addition, some international pharmacies like the American Pharmacy of Tokyo sell Western products, but the prices are more expensive. 2. Differences between pharmacies and drugstores? In Japanese, the word for pharmacy is "Yakkyoku". Generally, they are open from 9:00 am to 06:00 pm on weekdays and Saturda Continue reading >>

Inisync Combination Tablets Now Available For The Treatment Of Type 2 Diabetes In Japan

Inisync Combination Tablets Now Available For The Treatment Of Type 2 Diabetes In Japan

Inisync Combination Tablets Now Available for the Treatment of Type 2 Diabetes in Japan InisyncCombination Tablets Now Available forthe Treatment of Type 2 Diabetes in Japan Osaka, Japan, November 29, 2016- Takeda Pharmaceutical Company Limited TSE: 4502 Takeda today announced that InisyncCombination Tablets, a fixed-dose combination of Nesinageneric name: alogliptin benzoate and metformin hydrochloride hereinafter metformin, is now available in Japan for the treatment of type 2 diabetes. Inisync combination tablets combine 25 mg alogliptin and 500 mg metformin, which is orally administered once daily. Nesina is a once-daily dipeptidyl peptidase-IV DPP-4 inhibitor*, and metformin is biguanide that inhibits sugar production in the liver administered twice or three times daily. Both of them are widely used as therapeutic drugs for the treatment of diabetes. Inisync is the only combination administered once daily of a DPP-4 inhibitor and metformin in Japan. The approval for Inisync was granted based on the efficacy and safety data in the existing clinical studies related to Nesina and the Phase III study for Inisync in Japan in which the compounds of this combination, Nesina and metformin, were concomitantly administered. Pathology and treatment of type 2 diabetes are complex and the needs of patients and the treatment options have diversified. said Masato Iwasaki, Ph.D., Director and President, Japan Pharma Business Unit of Takeda. We have launched the once-weekly DPP-4 inhibitor, Zafatek, last year. We continue our efforts such that our newly launched product, Inisync combination tablets can be utilized as a new treatment option and we continue to contribute to healthcare professionals and patients in Japan through therapeutic drug advances for the treatment of diabetes Continue reading >>

A Double-blinded Trial Comparing The Efficacy And Safety Of Insulin Degludec/liraglutide And Insulin Degludec Both In Combination With Metformin In Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Or Pre- Ix/combination Insulin Therapy And Oral Anti-diabetic Drugs (dual Ii Japan)

A Double-blinded Trial Comparing The Efficacy And Safety Of Insulin Degludec/liraglutide And Insulin Degludec Both In Combination With Metformin In Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Or Pre- Ix/combination Insulin Therapy And Oral Anti-diabetic Drugs (dual Ii Japan)

Change in body weight [TimeFrame:Week 0, week 26] Change in fasting plasma glucose (FPG) [TimeFrame:Week 0, week 26] Number of treatment emergent severe or blood glucose (BG) confirmed hypoglycaemic episodes [TimeFrame:During 26 weeks of treatment] Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Male or female Japanese subjects, age at least 20 years at the time of signing informed consent T2DM (type 2 diabetes mellitus) subjects (diagnosed clinically) for at least 6 months prior to screening HbA1c (glycosylated haemoglobin) 7.5-11.0 per cent [58 mmol/mol-97 mmol/mol] (both inclusive) by central laboratory analysis Subjects on stable daily insulin doses for at least 60 days prior to screening administered once or twice daily, either as basal insulin (e.g. IDeg, insulin glargine, insulin detemir, NPH insulin) or pre-mix/combination insulin (e.g. biphasic insulin aspart, insulin degludec/insulin aspart). Total daily insulin dose in the previous 60 days should be within 20-50 units, both inclusive, and on the day of screening, but fluctuations of plus/minus 20 per cent within the 60 days prior to screening are acceptable. The specified insulin treatment should be administered in combination with a stable daily dose of metformin within current approved Japanese label for at least 60 days prior to screening - additio Continue reading >>

Effects Of Replacing Metformin With Pioglitazone On Glycemic Control In Japanese Patients With Poorly Controlled Type 2 Diabetes Mellitus: A 12-week, Open-label, Prospective Study

Effects Of Replacing Metformin With Pioglitazone On Glycemic Control In Japanese Patients With Poorly Controlled Type 2 Diabetes Mellitus: A 12-week, Open-label, Prospective Study

Volume 69, Issue 4 , August 2008, Pages 364-377 Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study Author links open overlay panel ShinjiSakaueMD1 Background: Insulin resistance is a critical aspect of the pathophysiology of type 2 diabetes mellitus and is also associated with other risk factors for cardiovascular disease (eg, dyslipidemia and hypertension). Accordingly, insulin resistance is a possible target for lowering plasma glucose concentration and preventing diabetic macroangiopathy. Biguanides, such as metformin, and thiazolidinediones (TZDs), such as pioglitazone, improve insulin resistance. Objectives: The aims of this study were to assess the effects of replacing a biguanide with a TZD on glycemic control in patients with poorly controlled type 2 diabetes mellitus, and also to identify the factors affecting interpatient variation in the effects of treatment change. Methods: This was a 12-week, open-label, prospective study in which previously prescribed metformin (500 or 750 mg/d) was replaced with pioglitazone (15 or 30 mg/d) in patients with poorly controlled type 2 diabetes mellitus. Patients with a glycosylated hemoglobin (HbA1c) concentration >7% despite treatment with diet, exercise, and hypoglycemic agents other than TZDs were eligible for the study. Patients who never received TZDs were also eligible for inclusion. Vital signs, metabolic parameters, and arterial stiffness were assessed at baseline and after 12 weeks of treatment with pioglitazone. The primary end point was change in HbA1c concentration after replacing metformin with pioglitazone. Tolerability was assessed by medical history, physical examination, and labor Continue reading >>

Long-term Treatment Study Of Global Standard Dose Metformin In Japanese Patients With Type 2 Diabetes Mellitus

Long-term Treatment Study Of Global Standard Dose Metformin In Japanese Patients With Type 2 Diabetes Mellitus

, Volume 8, Issue3 , pp 286295 | Cite as Long-term treatment study of global standard dose metformin in Japanese patients with type 2 diabetes mellitus In 169 Japanese patients with type 2 diabetes mellitus with blood glucose levels that were inadequately controlled with diet and exercise therapy alone, or with diet and exercise therapy plus a sulfonylurea (SU) drug, we evaluated the safety and efficacy of global standard dose metformin given up to a maximum daily dose of 2250mg for 54weeks. The changes in HbA1c from baseline to the final evaluation visit were 1.320.76% for metformin monotherapy and 1.290.81% for metformin plus SU, both significantly lower than baseline. The incidences of adverse events and adverse drug reactions were 91.1% (154/169 patients) and 67.5% (114/169 patients), respectively. The most common adverse events were gastrointestinal symptoms, and most of the gastrointestinal symptoms were considered by investigators to be related to metformin treatment. An increased blood lactic acid level was observed in three subjects (1.8%); however, no clinical symptoms were reported, and there was no increase in mean lactic acid concentration throughout the evaluation period. Symptoms of hypoglycemia were reported in 16patients, all receiving metformin plus SU, but none received metformin monotherapy. There was a decrease in mean body weight. Global standard dose metformin may be useful for maintaining good blood glucose control over the long term in the treatment of type 2 diabetes mellitus in Japanese patients. MetforminLong-term treatmentBMIBlood lipid level This is a preview of subscription content, log in to check access We thank the study participants, the investigators and contributors from each of the study sites. These studies were funded by Sumitomo Continue reading >>

High-dose Metformin Safe, Effective In Japanese Adults With Type 2 Diabetes

High-dose Metformin Safe, Effective In Japanese Adults With Type 2 Diabetes

In Japanese adults with poorly controlled type 2 diabetes, high doses of metformin administered twice or three times daily improved fasting plasma glucose and 24-hour glycemic profile in a dose-dependent fashion, according to findings reported in the Journal of Diabetes Investigation. “While the usual dosage of metformin is over 2,000 mg per day in Europe and the USA, the maximum dose allowed for clinical use in Japan has long been limited to 750 mg per day, which is less than half that of Western countries,” Hiroshi Ikegami, MD, PhD, of the department of endocrinology, metabolism and diabetes at Kindai University in Osaka, Japan, and colleagues wrote. “In addition, the recommended prescription of the maximum dose of metformin in Japan (750 mg per day) has been via 250-mg tablets administered three times per day. ... These differences in dosage and dosing frequency of metformin between Japan and Western countries have made it difficult to translate the results of clinical trials in Western countries to Japanese patients.” In two prospective studies, Ikegami and colleagues analyzed data from 71 Japanese patients with type 2 diabetes recruited between August 2011 and October 2016 from Kindai University Hospital (39 men; mean age, 61 years; mean BMI, 27 kg/m²; mean diabetes duration, 8.4 years; mean FPG, 7.5 mmol/L). All patients were provided standard meals recommended by the Japan Diabetes Society, and treatment with metformin was not initiated until patient FPG reached 11 mmol/L or less, to minimize the confounding effect of an initial improvement in glycemic control due to hospitalization. In the total cohort, 14 patients were treated with metformin monotherapy, whereas 54 patients were prescribed metformin as an add-on therapy to other antidiabetes medication Continue reading >>

The First Human Clinical Study For Nmn Has Started In Japan

The First Human Clinical Study For Nmn Has Started In Japan

In the recently published review in npj Aging and Mechanisms of Disease, Imai and Guarente 1 have provided a stimulating review about the role of nicotinamide adenine dinucleotide (NAD) in aging. The best known intervention against aging is calorie restriction, which is now recognized to be at the center of aging research. In 2000, Imai et al. 2 published a seminal paper in Nature entitled Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. In this paper, they proposed a possible mechanism underlying the benefit of calorie restrictionSir2 upregulator. Since then, Sir2 family proteins, now called sirtuins, and NAD have attracted researchers significant attention for the intervention to promote longevity. The coupling of sirtuin activity and NAD breakdown is a unique mechanism, and the authors portray it with the apt idiom it takes two to tango. Indeed, as in tango, both sirtuins and NAD are necessary for healthy aging and longevity. When NAD levels decrease with aging, the NAD/sirtuin tango falters. The intervention against aging is now an emerging application. Last year, Kaeberlein et al. 3 described eight possible interventions as disease preventive methods. The interventions include: dietary restriction, exercise, mechanistic target of rapamycin (mTOR) inhibitors, metformin and acarbose, NAD precursors and sirtuin activators, modifiers of senescence and telomore dysfunction, hormonal and circulating factors, and mitochondria-targeted therapeutics. Among them, dietary restriction (calorie restriction) and exercise appear to be the realistic interventions, but both requires modest lifestyle modification which may be difficult for some individuals to implement. mTOR inbibitors, as well as telomere modifiers, can be good practica Continue reading >>

Safety And Efficacy Of Metformin Up-titration In Japanese Patients With Type 2 Diabetes Mellitus Treated With Vildagliptin And Low-dose Metformin.

Safety And Efficacy Of Metformin Up-titration In Japanese Patients With Type 2 Diabetes Mellitus Treated With Vildagliptin And Low-dose Metformin.

Generate a file for use with external citation management software. Expert Opin Pharmacother. 2017 Dec;18(18):1921-1928. doi: 10.1080/14656566.2017.1404576. Epub 2017 Nov 15. Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin. a Department of Metabolism & Endocrinology , Juntendo University Graduate School of Medicine , Tokyo , Japan. b Center for Therapeutic Innovations in Diabetes , Juntendo University Graduate School of Medicine , Tokyo , Japan. d Sportology Center , Juntendo University Graduate School of Medicine , Tokyo , Japan. e Naka Memorial Clinic , Ibaragi , Japan. c Center for Identification of Diabetic Therapeutic Targets , Juntendo University Graduate School of Medicine , Tokyo , Japan. This study investigated the safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin (100mg/day) and low-dose metformin (500 or 750mg/day). Fifty patients were randomly allocated to the control group (maintaining the initial low-dose of metformin) and the dose increase group (up-titrating of metformin to 1,500-2,250mg/day) for 24weeks. The primary outcome was change in HbA1c from baseline to 24weeks. Among the 25 patients allocated to the dose increase group, four patients were not able to complete the study protocol because of gastrointestinal symptoms. HbA1c in the dose increase group was significantly but modestly lower than in the control group (change in HbA1c: 0.220.57 vs. -0.150.58%, group comparison, P<0.05). The dose increase group did not gain weight during the study period, and no hypoglycemic events were reported in both groups. The rate of gastrointestinal symptoms in the dose increase group was profoun Continue reading >>

Medication - Japan Forum

Medication - Japan Forum

I'm travelling to Japan in a couple of weeks from the UK to Dubai then to Tokyo, Our stop over in Dubai is 2-3 hours. Now the questions I have is, is the medication I need to take legal in Japan and Dubai? I need to take Propranolol Mr 80mg tablets but sometimes they are called half inderal and then I also need to take Metformin Hydrochloride 500mg Oral solution its a medicine so its liquid and my recent bottles have been in 150ml bottles. I'm also wanting to take Rennies and Imodium instant melts just incase I'm the kind of person who likes to be prepared. So has anyone taken these medications into Japan and Dubai before? I say Dubai because apparently you get searched in that airport to and if I need to put these in my carry on they will obviously see it, or is this the kind of medication i can put in my checked baggage? I'm going to get a dr's letter for the first two meds and take my prescription with me but I've read horror storys that this hasn't been enough in some cases. I dont mind put in it in my checked bag as long as they are all legal to take into these countries. Thanks First of all, why don't you ask your MD to change Metformin Hydrochloride oral solution to pills? That way you can carry them in your carryon bag without worrying about the liquid limitation. You should never put your Rx meds in checkin luggage in case they lose your luggage, so I recommend putting Metformin and Propranolol in your carry on. Antacid and anti-diarrhea meds can be easily obtained in a pharmacy anywhere in Japan, so I'd put them in the checkin luggage. Anyway all medications you mentioned can be brought into Japan without a Dr's letter or Rx (I'm a physician.) I cant swallow the metformin tablet thats why i have it as a liquid I forgot to say is paracetamol medicine ok if its Continue reading >>

More in diabetes